Candel therapeutics provides corporate update and highlights strong pipeline momentum and key value drivers for 2025

Needham, mass., jan. 13, 2025 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the company's viral immunotherapy portfolio and provided an update on the company's cash position and upcoming 2025 milestones.
CADL Ratings Summary
CADL Quant Ranking